Rivastigmine Tartrate
Product Images NDC 68151-4134

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 68151-4134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A line graph titled 'Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment in Study 1' showing mean change (±SEM) in ADAS-cog rating over weeks during treatment (0, 12, 18, 26) for three groups: 6 to 12 mg dose, 1 to 4 mg dose, and placebo. The graph illustrates clinical improvement with the 6 to 12 mg group and clinical decline with placebo and lower dose groups over the 26-week period.*

FDA Label Image

Figure2 (Figure2)

A cumulative percentage line graph depicting patients completing 26 weeks of double-blind treatment with Rivastigmine Tartrate and placebo, showing changes from baseline ADAS-cog scores. The x-axis shows change from baseline, and the y-axis shows cumulative percentage of patients. Lines represent three groups: 6 to 12 mg, 1 to 4 mg, and placebo. The graph also includes a table summarizing percentages of patients with specified changes in ADAS-cog scores for each treatment group.*

FDA Label Image

Figure3 (Figure3)

A bar chart showing the frequency distribution of CIBIC-Plus scores at Week 26 in Study 1 for Rivastigmine Tartrate. The x-axis lists CIBIC-Plus ratings ranging from Markedly Improved to Markedly Worse. The y-axis represents the percentage of patients. Three groups are compared: Placebo, 1 to 4 mg, and 6 to 12 mg doses, each represented by different colored bars.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting the time-course change from baseline in ADAS-cog scores over 26 weeks of treatment for patients on Rivastigmine Tartrate. It compares three groups: 6 to 12 mg dose, 1 to 4 mg dose, and placebo, showing clinical improvement or decline across weeks 0, 12, 18, and 26 with error bars indicating SEM.*

FDA Label Image

Figure5 (Figure5)

A cumulative percentage line graph showing patients completing 26 weeks of double-blind treatment with changes in baseline ADAS-cog scores. The graph compares three groups: 6 to 12 mg, 1 to 4 mg, and placebo, illustrating their change from baseline and cumulative percentage of patients. An inset table summarizes the percentage of patients achieving ADAS-cog changes of -7, -4, and 0 for each treatment group.*

FDA Label Image

Figure6 (Figure6)

A bar chart titled 'Figure 6 Frequency Distribution of CIBIC-Plus Scores at Week 26 in Study 2' showing the percentage of patients across different CIBIC-Plus rating categories (Markedly Improved to Markedly Worse). Three groups are compared: Placebo, 1 to 4 mg, and 6 to 12 mg. The Y-axis represents the percentage of patients, and the X-axis categories show levels of improvement or worsening.*

FDA Label Image

Figure7 (Figure7)

A line graph depicting the time course of change from baseline in ADAS-cog scores over 24 weeks of treatment in Study 4. The x-axis represents weeks during treatment (0, 16, 24), and the y-axis shows mean change from baseline along with SEM. Two lines compare Rivastigmine Tartrate and placebo effects, illustrating clinical improvement or decline in ADAS-cog scores.*

FDA Label Image

Figure8 (Figure8)

A bar chart showing the distribution of ADCS-CGIC scores for patients completing 24 weeks of treatment in Study 4 comparing Rivastigmine Tartrate and placebo groups. The X-axis lists ADCS CGIC ratings from markedly improved to markedly worse, and the Y-axis shows the percentage of patients in each category. Bars are color-coded for Rivastigmine Tartrate and placebo.*

FDA Label Image

Label Image (Lbl681514134)

Packaging label for Rivastigmine Tartrate 1.5 mg capsules. The label includes manufacturer information (MFG: SUN), lot number, expiration date (07/14), and a barcode. The labeler is Carilion Materials Management, with product NDC 68151-4134. The label indicates prescription use only.*

FDA Label Image

Structure (Structure)

Chemical structure of Rivastigmine Tartrate showing its molecular components, including aromatic ring, carbonyl groups, and side chains with nitrogen and methyl groups, accompanied by the tartrate moiety (C4H6O6).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.